Full text is available at the source.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico··
IKBKE may increase resistance to chemotherapy by raising MGMT levels in glioblastoma
Updated
Abstract
IKBKE enhances glioblastoma cell resistance to temozolomide (TMZ) by activating the AKT/NF-κB signaling pathway.
- IKBKE upregulates the expression of the DNA repair enzyme MGMT, which may contribute to drug resistance.
- Knockdown of IKBKE in glioblastoma cells increases apoptosis and reduces cell proliferation.
- In vivo experiments show that IKBKE knockdown suppresses tumor development when combined with TMZ.
- Overexpression of IKBKE diminishes the therapeutic effects of TMZ.
Simplified
PURPOSE: Glioblastoma multiforme (GBM) is the most common and aggressive malignant type of brain tumor. Despite advances in diagnosis and therapy, the prognosis of patients with GBM has remained dismal. Multidrug resistance and high recurrence are two of the major challenges in successfully treating brain tumors. IKBKE (inhibitor of nuclear factor kappa-B kinase subunit epsilon) is a major oncogenic protein in tumors and can inhibit glioblastoma cell proliferation, migration, and tumorigenesis. Our study aimed to investigate the mechanism of IKBKE enhancing the resistance of glioma cells to temozolomide.
METHODS: For the in vitro experiments, LN18 and U118 glioblastoma cells were treated with a combination of sh/oe-IKBKE lentivirus and TMZ. Cell proliferation was determined by the EdU assay and colony formation assays. Apoptosis was analyzed by the TUNEL assay. In vivo, LN18 NC and LN18 sh-IKBKE cells were implanted into the cerebrums of nude mice to detect the effect of combination therapy. The protein and mRNA levels were assayed by western blot, immunohistochemistry, and qRT-PCR.
RESULTS: In this study, we demonstrated that IKBKE enhances the resistance of glioblastoma cells to temozolomide (TMZ) by activating the AKT/NF-κB signaling pathway to upregulate the expression of the DNA repair enzyme o6-methylguanine-dna methyltransferase (MGMT). In glioblastoma cells, IKBKE knockdown enhances apoptosis and suppresses cell proliferation, clone formation, and tumor development in vivo induced by TMZ. However, overexpression of IKBKE reduces the effects of TMZ.
CONCLUSION: Our studies suggest that inhibition of IKBKE can enhance the therapeutic effect of TMZ on GBM in vitro and in vivo, providing new research directions and therapeutic targets for the treatment of GBM.
Related papers
Oct '21
Blocking serine production may improve temozolomide treatment by lowering DNA repair and oxidative damage in brain cancer
top 20% journal
cited by 29 papers
journal article
Apr '18
Blocking NF-κB may fight glioma and lower resistance to chemotherapy by reducing MGMT gene activity
top 5% journal
cited by 58 papers
research support, non-u.s. gov't
Dec '12
Blocking antioxidant production may increase temozolomide’s indirect cancer-killing effect in brain tumors
top 5% journal
cited by 27 papers
research support, non-u.s. gov't
Oct '19
Nuclear factor I A may increase resistance to temozolomide in glioblastoma by activating the inflammation control pathway
cited by 25 papers
journal article
Oct '24
AP-2α may reduce chemotherapy resistance in recurring brain tumors by lowering MGMT levels and increasing DNA damage
cited by 1 paper
journal article
May '19
Lnc-TALC increases DNA repair enzyme levels by controlling the c-Met pathway through competing with miR-20b-3p
top 2% journal
cited by 144 papers
research support, non-u.s. gov't
Jan '21
How the RIP2/NF-κB/MGMT pathway controls temozolomide resistance in brain tumor cells
top 10% journal
cited by 40 papers
research support, non-u.s. gov't
Feb '22
Temozolomide increases COX-2 levels in human brain cancer cells
top 20% journal
cited by 19 papers
journal article
Oct '22
NMDA receptor activity may increase temozolomide resistance by raising MGMT levels in glioblastoma cells
cited by 9 papers
journal article
Jul '24
TAGLN2’s role in aggressive brain tumors: linked to cell type changes and resistance to chemotherapy
top 5% journal
cited by 14 papers
journal article